自噬抑制剂联合大剂量CDK4/6抑制剂为晚期HR+/HER2-乳腺癌提供了新的希望。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-05-09 DOI:10.1016/j.medj.2024.100571

Li-Ping Ge, Yi-Zhou Jiang

{"title":"自噬抑制剂联合大剂量CDK4/6抑制剂为晚期HR+/HER2-乳腺癌提供了新的希望。","authors":"Li-Ping Ge, Yi-Zhou Jiang","doi":"10.1016/j.medj.2024.100571","DOIUrl":null,"url":null,"abstract":"Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) with endocrine therapy are standard for advanced hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. However, treatment options following resistance to CDK4/6is remain poorly defined. Gong et al. conducted a phase 1b/2 trial, demonstrating that autophagy inhibitors combined with high-dose CDK4/6is are well tolerated and effective in patients with advanced HR+/HER2- breast cancer resistant to first-line CDK4/6i therapy.1.","PeriodicalId":29964,"journal":{"name":"Med","volume":"6 5","pages":"100571"},"PeriodicalIF":12.8000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination of autophagy inhibitors with high-dose CDK4/6 inhibitors offers new hope for advanced HR+/HER2- breast cancer.\",\"authors\":\"Li-Ping Ge, Yi-Zhou Jiang\",\"doi\":\"10.1016/j.medj.2024.100571\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) with endocrine therapy are standard for advanced hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. However, treatment options following resistance to CDK4/6is remain poorly defined. Gong et al. conducted a phase 1b/2 trial, demonstrating that autophagy inhibitors combined with high-dose CDK4/6is are well tolerated and effective in patients with advanced HR+/HER2- breast cancer resistant to first-line CDK4/6i therapy.1.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"6 5\",\"pages\":\"100571\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2024.100571\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2024.100571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

周期蛋白依赖性激酶4/6抑制剂（CDK4/6is）配合内分泌治疗是晚期激素受体阳性/HER2阴性（HR+/HER2-）乳腺癌的标准治疗方法。然而，cdk4 /6耐药后的治疗选择仍然不明确。Gong等进行的1b/2期试验表明，自噬抑制剂联合大剂量CDK4/6is对一线CDK4/6i治疗耐药的晚期HR+/HER2-乳腺癌患者具有良好的耐受性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Combination of autophagy inhibitors with high-dose CDK4/6 inhibitors offers new hope for advanced HR+/HER2- breast cancer.

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) with endocrine therapy are standard for advanced hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. However, treatment options following resistance to CDK4/6is remain poorly defined. Gong et al. conducted a phase 1b/2 trial, demonstrating that autophagy inhibitors combined with high-dose CDK4/6is are well tolerated and effective in patients with advanced HR+/HER2- breast cancer resistant to first-line CDK4/6i therapy.¹.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.